ALK-Abello (ALKb)

Currency in DKK
239.20
-5.80(-2.37%)
Closed·
ALKb is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
238.60244.00
52 wk Range
191.80271.40
Key Statistics
Prev. Close
245
Open
243.8
Day's Range
238.6-244
52 wk Range
191.8-271.4
Volume
201.59K
Average Volume (3m)
229.04K
1-Year Change
3.0146%
Book Value / Share
32.79
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALKb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
289.67
Upside
+21.10%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth

ALK-Abello News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 289.67
(+21.10% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Berenberg
Buy300.00+25.42%305.00MaintainAug 21, 2026
Jefferies
Buy285.00+19.15%255.00MaintainMay 06, 2026

ALK-Abello Earnings Call Summary for Q3/2026

  • ALK reported Q3 2026 revenue of DKK 1.76B, up 15% in local currencies, driven by 35% tablet sales growth; shares fell 4.5% on margin concerns.
  • EBIT margin compressed to 27% from 28% year-over-year as capacity costs rose 20%; management pledged no further cost step-up planned for 2027.
  • Company reaffirmed 2026 guidance of 16-17% revenue growth and 27% EBIT margin; free cash flow expected to exceed DKK 1.1B for the year.
  • ACARIZAX met Phase III trial endpoint in China; filing expected H1 2027 with potential late-2028 launch targeting 100M house dust mite allergy patients.
  • Germany rebate increase effective January 2027 poses profitability risk; neffy launch progressing but remains modest revenue contributor in early stage.
Last Updated: 11/17/2026, 11:32 PM
Read Full Transcript

Earnings

Latest Release
Nov 16, 2026
EPS / Forecast
1.60 / 1.70
Revenue / Forecast
1.76B / 1.72B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.31
Dividend Yield
0.67%
Industry Median 3.85%
Annualized payout
1.60
Paid annually
5-Years Growth
-
Growth Streak

ALKb Income Statement

Compare ALKb to Peers and Sector

Metrics to compare
ALKb
Peers
Sector
Relationship
P/E Ratio
37.8x16.3x−0.2x
PEG Ratio
1.431.490.00
Price/Book
7.3x2.7x2.6x
Price / LTM Sales
7.5x1.6x2.6x
Upside (Analyst Target)
21.1%14.1%76.9%
Fair Value Upside
Unlock30.4%14.9%Unlock

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy. In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies. Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy’s Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

Employees
2795
Market
Denmark

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
47.72M21.51%11.42B
Other Institutional Investors
78.66M35.45%18.82B
Public Companies & Retail Investors
95.50M43.04%22.84B
Total
221.88M100.00%53.07B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Lundbeckfonden BioCapital40.45%89,752,38021,468,769
ATP5.03%11,156,3292,668,594

People Also Watch

774.5
NKT
-5.55%
60.40
HLUNb
-2.27%
907.6
PNDORA
-1.60%
580.00
MUVGn
+0.90%
118.32
ENR1n
-6.61%

FAQ

What Is the ALK-Abello (ALKb) Stock Price Today?

The ALK-Abello stock price today is 239.20 DKK.

What Stock Exchange Does ALK-Abello Trade On?

ALK-Abello is listed and trades on the Copenhagen Stock Exchange.

What Is the Stock Symbol for ALK-Abello?

The stock symbol for ALK-Abello is "ALKb."

Does ALK-Abello Pay Dividends? What’s The Current Dividend Yield?

The ALK-Abello dividend yield is 0.7%%.

What Is the ALK-Abello Market Cap?

As of today, ALK-Abello market cap is 53.07B DKK.

What Is ALK-Abello's Earnings Per Share (TTM)?

The ALK-Abello EPS (TTM) is 6.31.

When Is the Next ALK-Abello Earnings Date?

ALK-Abello will release its next earnings report on Feb 09, 2027.

From a Technical Analysis Perspective, Is ALKb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has ALK-Abello Stock Split?

ALK-Abello has split 1 times.

How Many Employees Does ALK-Abello Have?

ALK-Abello has 2795 employees.

What is the current trading status of ALK-Abello (ALKb)?

As of Nov 21, 2026, ALK-Abello (ALKb) is trading at a price of 239.20 DKK, with a previous close of 245.00 DKK. The stock has fluctuated within a day range of 238.60 DKK to 244.00 DKK, while its 52-week range spans from 191.80 DKK to 271.40 DKK.

What Is ALK-Abello (ALKb) Price Target According to Analysts?

The average 12-month price target for ALK-Abello is 289.67 DKK, with a high estimate of 303 DKK and a low estimate of 275 DKK. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +21.10% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.